203 related articles for article (PubMed ID: 2091733)
21. In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium.
Sarifakioglu E; Seçkin D; Demirbilek M; Can F
Clin Exp Dermatol; 2007 Nov; 32(6):675-9. PubMed ID: 17714532
[TBL] [Abstract][Full Text] [Related]
22. Azole resistance in Candida albicans.
Smith KJ; Warnock DW; Kennedy CT; Johnson EM; Hopwood V; Van Cutsem J; Vanden Bossche H
J Med Vet Mycol; 1986 Apr; 24(2):133-44. PubMed ID: 3014106
[TBL] [Abstract][Full Text] [Related]
23. Cytochrome P450 of fungi: primary target for azole antifungal agents.
Yoshida Y
Curr Top Med Mycol; 1988; 2():388-418. PubMed ID: 3288361
[TBL] [Abstract][Full Text] [Related]
24. A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity.
Hof H
Mycoses; 2006; 49 Suppl 1():2-6. PubMed ID: 16961575
[TBL] [Abstract][Full Text] [Related]
25. Effects of antifungal agents on ergosterol biosynthesis in Candida albicans and Trichophyton mentagrophytes: differential inhibitory sites of naphthiomate and miconazole.
Morita T; Nozawa Y
J Invest Dermatol; 1985 Nov; 85(5):434-7. PubMed ID: 3902987
[TBL] [Abstract][Full Text] [Related]
26. Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents.
Odds FC; Webster CE; Abbott AB
J Antimicrob Chemother; 1984 Aug; 14(2):105-14. PubMed ID: 6094418
[TBL] [Abstract][Full Text] [Related]
27. Evolution of ergosterol biosynthesis inhibitors as fungicidal against Candida.
Ahmad A; Khan A; Manzoor N; Khan LA
Microb Pathog; 2010 Jan; 48(1):35-41. PubMed ID: 19835945
[TBL] [Abstract][Full Text] [Related]
28. Terbinafine: mode of action and properties of the squalene epoxidase inhibition.
Ryder NS
Br J Dermatol; 1992 Feb; 126 Suppl 39():2-7. PubMed ID: 1543672
[TBL] [Abstract][Full Text] [Related]
29. Strong antifungal activity of SS750, a new triazole derivative, is based on its selective binding affinity to cytochrome P450 of fungi.
Matsumoto M; Ishida K; Konagai A; Maebashi K; Asaoka T
Antimicrob Agents Chemother; 2002 Feb; 46(2):308-14. PubMed ID: 11796335
[TBL] [Abstract][Full Text] [Related]
30. Effects of terconazole and other azole antifungal agents on the sterol and carbohydrate composition of Candida albicans.
Pfaller MA; Riley J; Koerner T
Diagn Microbiol Infect Dis; 1990; 13(1):31-5. PubMed ID: 2184984
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
Yu S; Chai X; Hu H; Yan Y; Guan Z; Zou Y; Sun Q; Wu Q
Eur J Med Chem; 2010 Oct; 45(10):4435-45. PubMed ID: 20675019
[TBL] [Abstract][Full Text] [Related]
32. Fungal infections of the skin: infection process and antimycotic therapy.
Borgers M; Degreef H; Cauwenbergh G
Curr Drug Targets; 2005 Dec; 6(8):849-62. PubMed ID: 16375669
[TBL] [Abstract][Full Text] [Related]
33. Potential dual inhibition of SE and CYP51 by eugenol conferring inhibition of Candida albicans: Computationally curated study with experimental validation.
Prajapati J; Goswami D; Dabhi M; Acharya D; Rawal RM
Comput Biol Med; 2022 Dec; 151(Pt A):106237. PubMed ID: 36327880
[TBL] [Abstract][Full Text] [Related]
34. The biology and chemistry of antifungal agents: a review.
Kathiravan MK; Salake AB; Chothe AS; Dudhe PB; Watode RP; Mukta MS; Gadhwe S
Bioorg Med Chem; 2012 Oct; 20(19):5678-98. PubMed ID: 22902032
[TBL] [Abstract][Full Text] [Related]
35. Miconazole, a pharmacological barrier to skin fungal infections.
Piérard GE; Hermanns-Lê T; Delvenne P; Piérard-Franchimont C
Expert Opin Pharmacother; 2012 Jun; 13(8):1187-94. PubMed ID: 22568580
[TBL] [Abstract][Full Text] [Related]
36. Design and synthesis of potential inhibitors of the ergosterol biosynthesis as antifungal agents.
Chung SK; Lee KW; Kang HI; Yamashita C; Kudo M; Yoshida Y
Bioorg Med Chem; 2000 Oct; 8(10):2475-86. PubMed ID: 11058043
[TBL] [Abstract][Full Text] [Related]
37. Bactericidal and inhibitory effects of azole antifungal compounds on Mycobacterium smegmatis.
Jackson CJ; Lamb DC; Kelly DE; Kelly SL
FEMS Microbiol Lett; 2000 Nov; 192(2):159-62. PubMed ID: 11064188
[TBL] [Abstract][Full Text] [Related]
38. [Cross-resistance of Candida albicans to several different families of antifungals with ergosterol biosynthesis-inhibiting activity].
Hiratani T; Yamaguchi H
Jpn J Antibiot; 1994 Feb; 47(2):125-8. PubMed ID: 8151906
[TBL] [Abstract][Full Text] [Related]
39. Sterol biosynthesis inhibitors. Secondary effects and enhanced in vivo efficacy.
Berg D; Plempel M; Büchel KH; Holmwood G; Stroech K
Ann N Y Acad Sci; 1988; 544():338-47. PubMed ID: 3214074
[TBL] [Abstract][Full Text] [Related]
40. Azole Resistance in Dermatophytes: Prevalence and Mechanism of Action.
Ghannoum M
J Am Podiatr Med Assoc; 2016; 106(1):79-86. PubMed ID: 26895366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
